TP53 and breast carcinoma: More interestingly, these overall data are also concordant with earlier work by Lin et al. outlining that antibody against integrin αvβ3, but not αvβ5, or RGD peptide specifically impede the initiation of ERK1/2- and p53-dependent resveratrol-induced apoptosis in human breast cancer cells MCF-7 or MDA-MB231, thereby supporting the notion that integrin αvβ3 carries a receptor site for resveratrol [24].